Why the study?
With increasing interest in anti-stromal therapies to improve cancer outcomes, the LOX family has emerged as a potential clinical target, motivating an examination of its dysregulation, preclinical therapeutics, and biomarker potential.
The LOX family of enzymes represents a potential clinical target for anti-stromal therapies and a diagnostic/prognostic marker in solid tumors.
Answers are grounded in this paper and cite their sources.
Should not yet guide anti-stromal decisions in solid tumors; leaves open prospective validation of LOX as target and marker.
The lysyl oxidase (LOX) family of enzymes are a major driver in the biogenesis of desmoplastic matrix at the primary tumour and secondary metastatic sites. With the increasing interest in and development of anti-stromal therapies aimed at improving clinical outcomes of cancer patients, the Lox family has emerged as a potentially powerful clinical target. This review examines how lysyl oxidase family dysregulation in solid cancers contributes to disease progression and poor patient outcomes, as well as an evaluation of the preclinical landscape of LOX family targeting therapeutics. We also discuss the suitability of the LOX family as a diagnostic and/or prognostic marker in solid tumours.
No takes yet. Share an insight, caveat, or question.
Setargew et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: